Home › NDC Lookup › Ingredients › Modafinil › 65862-0602-01
⚪image loading
(from DailyMed)

Modafinil 200 mg Tablet, 100-count — NDC 65862-602-01 (Billing 65862-0602-01)

by Aurobindo Pharma Limited · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Modafinil 200 mg Tablet from Aurobindo Pharma Limited, marketed since Sep 2012 and currently FDA-listed; retail pharmacies pay about $0.3436 per tablet (NADAC). It is the main listing for this product, which comes in 6 package sizes.

NDC 65862-0602-01
🏷️ FDA NDC (as labeled) 65862-602-01 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.3436 NADAC Per package$34.36 / 100 tablets Pack sizes6 compare ↓
Also priced by: Medicaid pays $0.9831/unit · Part D plans $0.5456/unit — full pricing hub ↓
Main listing for product 65862-602 · Also comes in: 30 tablets 65862-602-30 90 tablets 65862-602-90 500 tablets 65862-602-05 4000 tablets 65862-602-49 45000 tablets 65862-602-46
On market CIV ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65862-602-01
Product NDC 65862-602
11-digit billing NDC 65862060201
NCPDP billing unit EA — each (per item)
SPL Set ID a40d72c7-7a24-4b69-9071-7c7f8fe9ad79
DEA schedule CIV
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2012-09-27
Dosage form TABLET
Substance MODAFINIL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 61400024000320
GPI class Modafinil
GCN Seq No 041478
GCN 26102
HICL code 010865
Ingredient (HICL) Modafinil
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H8
Therapeutic class — intermediate (HIC2) Psychoactive Drugs (Continued 2)
HIC3 code H8Q
Therapeutic class — specific (HIC3) Narcolepsy And Sleep Disorder Therapy Agents
AHFS code 28:20.80.00
AHFS class Wakefulness-Promoting Agents
FDB label name MODAFINIL 200 MG TABLET
FDB brand name Modafinil
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 041478
  • GCN: 26102
  • GPI-14 (Medi-Span): 61400024000320
  • HICL (First Databank): 010865
  • AHFS class code: 28:20.80.00
Why two NDCs? The FDA registers this code as 65862-602-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65862-0602-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name MODAFINIL 200 MG TABLET Ingredient Modafinil
📖 What it is MedlinePlus · NLM

Modafinil is used to treat excessive sleepiness caused by narcolepsy (a condition that causes excessive daytime sleepiness) or shift work sleep disorder (sleepiness during scheduled waking hours and difficulty falling asleep or staying asleep during scheduled sleeping hours in people who work at night or on rotating shifts). Modafinil is also used along with breathing devices or other treatments to prevent excessive sleepiness caused by obstructive sleep apnea/hypopnea syndrome (OSAHS; a sleep disorder in which the patient briefly stops breathing or breathes shallowly many times during sleep a...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It helps adults stay awake when they have excessive sleepiness from narcolepsy, obstructive sleep apnea, or shift work disorder. In sleep apnea, it treats the sleepiness but not th...
  • Take it once a day by mouth. For narcolepsy or sleep apnea, take it in the morning. For shift work disorder, take it about an hour before your shift starts. Follow your prescriptio...
  • Common ones are headache, nausea, nervousness, anxiety, trouble sleeping, dizziness, and diarrhea. Most are mild to moderate. Let me know if they bother you or don't go away.
  • Yes. Stop the medicine and get help if you see any rash, or swelling of your face, lips, or throat. Also call if you notice new depression, mania, or odd thinking, or if you get ch...
📖 Read our full Modafinil guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.344 $34.36 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.9831 $98.31 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.5456 $54.56 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.711 $0.344
▼ Down 40% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
65862-0602-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE $0.3436 / ea $34.36 2012-09-27 — Active
65862-0602-05 65862-602-05 500 TABLET in 1 BOTTLE — — 2012-09-27 — Active
65862-0602-30 65862-602-30 30 TABLET in 1 BOTTLE $0.3436 / ea $10.31 2012-09-27 — Active
65862-0602-90 65862-602-90 90 TABLET in 1 BOTTLE — — 2012-09-27 — Active
65862-0602-46 65862-602-46 45000 TABLET in 1 BAG — — — — Active
65862-0602-49 65862-602-49 4000 TABLET in 1 BAG — — — — Active

You're viewing one of 6 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.3436 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 63% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 65862-0602-30?
Both are Modafinil 200 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 65862-0602-30 is the 30 tablets package.
What NDC number is used to bill for this package of Modafinil 200 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Modafinil 200 mg 00904-6792-04 Major 30 tablets $0.344 AB Availability likely —
Modafinil 200 mg 50268-0571-12 AvPAK 20 tablets $0.344 AB Availability likely —
Modafinil 200 mg 60505-2527-01 Apotex 100 tablets $0.344 AB Availability likely —
Modafinil 200 mgthis 65862-0602-01 Aurobindo 100 tablets $0.344 — Availability likely —
Modafinil 200 mg 68084-0721-21 American 30 tablets $0.344 AB Availability likely —
Modafinil 200 mg 69452-0343-13 Bionpharma 30 tablets $0.344 AB Availability likely —
Modafinil 200 mg 72578-0006-01 Viona 100 tablets $0.344 AB Availability likely —
Modafinil 200 mg 55253-0802-30 CIMA 30 tablets $0.356 AB Discontinued +3%
Modafinil 200 mg 60505-4852-03 Apotex 30 tablets $80.349 — Availability likely +23283%
Modafinil 200 mg 63459-0201-30 Cephalon, 30 tablets $80.349 — Availability likely +23283%
Modafinil 200 mg 23155-0605-01 Heritage 100 tablets — AB FDA listed —
Modafinil 200 mg 23155-0862-01 Heritage 100 tablets — AB FDA listed —
modafinil 200 mg 43353-0925-30 Aphena 30 tablets — AB FDA listed —
Modafinil 200 mg 46708-0386-10 Alembic 100 tablets — AB FDA listed —
Modafinil 200 mg 51407-0961-30 Golden 30 tablets — AB FDA listed —
Modafinil 200 mg 57237-0155-01 Rising 100 tablets — AB FDA listed —
Provigil 200 mg 60429-0010-30 Golden 30 tablets — AB FDA listed —
Modafinil 200 mg 62332-0386-10 Alembic 100 tablets — AB FDA listed —
Modafinil 200 mg 63629-7315-01 Bryant 30 tablets — AB FDA listed —
Modafinil 200 mg 68788-8280-03 Preferred 30 tablets — AB FDA listed —
Modafinil 200 mg 68788-8653-03 Preferred 30 tablets — AB FDA listed —
Modafinil 200 mg 70771-1052-01 Zydus 100 tablets — AB FDA listed —
Modafinil 200 mg 71205-0544-30 Proficient 30 tablets — AB FDA listed —
Modafinil 200 mg 71335-1173-01 Bryant 30 tablets — AB Discontinued —
Modafinil 200 mg 71335-2258-00 Bryant 100 tablets — AB FDA listed —
Modafinil 200 mg 71335-2501-00 Bryant 100 tablets — AB FDA listed —
Modafinil 200 mg 71610-0685-30 Aphena 30 tablets — AB FDA listed —
Modafinil 200 mg 71610-0873-30 Aphena 30 tablets — AB FDA listed —
Modafinil 200 mg 71610-0989-30 Aphena 30 tablets — AB FDA listed —
Modafinil 200 mg 71610-0991-30 Aphena 30 tablets — AB FDA listed —
Modafinil 200 mg 82804-0126-30 Proficient 30 tablets — AB FDA listed —
modafinil 200 mg 63285-0001-00 Patheon 19842 tablets — — FDA listed —
modafinil 200 mg 63552-0067-00 Patheon 40000 tablets — — FDA listed —
Modafinil 200 mg 87063-0309-01 ASCLEMED 100 tablets — AB FDA listed —
Modafinil 200 mg 87063-0307-01 ASCLEMED 100 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2012
On the market since
Sep 2012
📍
2026
Currently FDA-listed
14 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code65862
First marketedSep 2012
DEA scheduleCIV
Product typeDrug For Further Processing
Portfolio1,456 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
6.5K
Units reimbursed last 4 qtrs
243.2K
Gross reimbursed last 4 qtrs
$239.1K
Avg / prescription
$37.06
Avg / unit
$0.9831
Latest quarter Q1 2026
1.4KRx
Medicaid pays / ea
$0.9831
gross reimbursed
vs
NADAC / ea
$0.3436
acquisition cost
=
Spread
+$0.6395
+186% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
53% FFS 47% MCO
Fee-for-service · 3,412 Rx Managed care · 3,040 Rx
State Medicaid map
Alaska: 439 units · 59.9 per 100k residents AK Maine: no data reported ME Washington: 14,354 units · 184 per 100k residents WA Idaho: no data reported ID Montana: 360 units · 31.8 per 100k residents MT North Dakota: no data reported ND Minnesota: 6,082 units · 106 per 100k residents MN Wisconsin: 2,848 units · 48.2 per 100k residents WI Michigan: no data reported MI New York: 5,771 units · 29.5 per 100k residents NY Vermont: no data reported VT New Hampshire: 510 units · 36.4 per 100k residents NH Oregon: 1,438 units · 34.0 per 100k residents OR Nevada: 6,257 units · 196 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 12,208 units · 97.3 per 100k residents IL Indiana: 6,597 units · 96.1 per 100k residents IN Ohio: 9,026 units · 76.6 per 100k residents OH Pennsylvania: 8,698 units · 67.1 per 100k residents PA New Jersey: 1,560 units · 16.8 per 100k residents NJ Massachusetts: 1,471 units · 21.0 per 100k residents MA California: 91,254 units · 234 per 100k residents CA Utah: 5,906 units · 173 per 100k residents UT Colorado: 13,935 units · 237 per 100k residents CO Nebraska: no data reported NE Missouri: 2,977 units · 48.0 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 1,623 units · 18.6 per 100k residents VA Maryland: 360 units · 5.8 per 100k residents MD Connecticut: 618 units · 17.1 per 100k residents CT Rhode Island: no data reported RI Arizona: 7,364 units · 99.1 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 690 units · 9.7 per 100k residents TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 7,874 units · 172 per 100k residents LA Mississippi: no data reported MS Alabama: 3,720 units · 72.8 per 100k residents AL Georgia: 1,290 units · 11.7 per 100k residents GA D.C.: no data reported DC Hawaii: 750 units · 52.3 per 100k residents HI Texas: 6,302 units · 20.7 per 100k residents TX Florida: 20,951 units · 92.7 per 100k residents FL
Units reimbursed · per 100k residents
5.8237
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Colorado 237 /100k
2 California 234 /100k
3 Nevada 196 /100k
4 Washington 184 /100k
5 Utah 173 /100k
6 Louisiana 172 /100k
7 Minnesota 106 /100k
8 Arizona 99.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page65862-0602-01 6,452 Rx · $239,116
30 tablets65862-0602-30 3,735 Rx · $149,042
500 tablets65862-0602-05 No Medicaid data
90 tablets65862-0602-90 No Medicaid data
45000 tablets65862-0602-46 No Medicaid data
4000 tablets65862-0602-49 No Medicaid data
Drug total (last 4 qtrs): 10,187 Rx · 401,566 units · $388,158 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Modafinil (matched by generic name) — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Modafinil. CMS lists 2 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$4.9M
Claims incl. refills
103.8K
Beneficiaries
57.1K
Spend / beneficiary
$85.91
Spend / claim
$47.23
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 5 other package presentations of this same product, including 30 tablets (65862-0602-30), 90 tablets (65862-0602-90), 500 tablets (65862-0602-05). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65862-0601-01 · Aurobindo 65862-0603-30 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.